Skip to content
Screener

Ligand Pharmaceuticals LGND Unrealized Gains on Investments

Unrealized Gains on Investments at other companies

Roivant Sciences logo
Roivant SciencesROIV
$25K
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$516K-79.4%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$42K
Nektar Therapeutics logo
Nektar TherapeuticsNKTR

Other financials

Income statement

See full
Revenue$63.7M+33.7%
Operating income$8.6M+1.7%
Net income$48.5M+901%
EPS (diluted)$2.22+825%

Balance sheet

See full
Cash & equivalents$1.0B+1,388%
Total debt$1.1B+19,605%
Total equity$967.5M+16.9%
Total assets$2.2B+130%

Cash flow

See full
Operating cash flow$24.0M+52.0%
CapEx$26.0K-87.9%
Free cash flow$24.0M+53.9%

Valuation

See full
Market cap$5.89B+105%
Enterprise value$6.02B+114%
P/E29.9×
P/S20.3×+4.9×

Profitability

See full
Gross margin91.9%
Operating margin32.6%+24.0pp
Net margin67.9%+49.4pp
FCF margin45.2%+16.7pp

Returns & leverage

See full
Return on equity22%+16.9pp
Debt / equity1.2×+1.2×
Current ratio31.2×+25.7×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000886163-26-000044
June 30, 2026Amortized costGross unrealized gainsGross unrealized lossesEstimated fair value
Corporate notes/bonds52,307(130)52,177
Corporate equity securities20,85063,477(3,314)81,013
Commercial paper7,430(6)7,424
Total short-term investments$291,586$63,477$(4,007)$351,056
December 31, 2025
U.S. Government Agencies$175,780$89$(38)$175,831
Corporate notes/bonds124,24998(52)124,295
U.S. Treasuries113,055137(4)113,188

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Ligand Pharmaceuticals's unrealized gains on investments?
Ligand Pharmaceuticals (LGND) reported unrealized gains on investments of $63.48M in Q2 2026.
How has Ligand Pharmaceuticals's unrealized gains on investments changed year-over-year?
Ligand Pharmaceuticals's unrealized gains on investments increased by 2929.9% year-over-year, from $2.1M to $63.48M.
What is the long-term trend for Ligand Pharmaceuticals's unrealized gains on investments?
Over 5 years (2020 to 2025), Ligand Pharmaceuticals's unrealized gains on investments has grown at a 114.6% compound annual growth rate (CAGR), from $1.3M to $59.2M.
What does unrealized gains on investments mean?
The total unrealized gains on investments, typically related to available-for-sale securities.

Ask your AI about Ligand Pharmaceuticals's unrealized gains on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude